Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Silencing miR-21-5p in sensory neurons reverses neuropathic allodynia via activation of TGF-β–related pathway in macrophages
Lynda Zeboudj, … , David Chambers, Marzia Malcangio
Lynda Zeboudj, … , David Chambers, Marzia Malcangio
Published April 18, 2023
Citation Information: J Clin Invest. 2023;133(11):e164472. https://doi.org/10.1172/JCI164472.
View: Text | PDF
Research Article Immunology Neuroscience

Silencing miR-21-5p in sensory neurons reverses neuropathic allodynia via activation of TGF-β–related pathway in macrophages

  • Text
  • PDF
Abstract

Neuropathic pain remains poorly managed by current therapies, highlighting the need to improve our knowledge of chronic pain mechanisms. In neuropathic pain models, dorsal root ganglia (DRG) nociceptive neurons transfer miR-21 packaged in extracellular vesicles to macrophages that promote a proinflammatory phenotype and contribute to allodynia. Here we show that miR-21 conditional deletion in DRG neurons was coupled with lack of upregulation of chemokine CCL2 after nerve injury and reduced accumulation of CCR2-expressing macrophages, which showed TGF-β–related pathway activation and acquired an M2-like antinociceptive phenotype. Indeed, neuropathic allodynia was attenuated after conditional knockout of miR-21 and restored by TGF-βR inhibitor (SB431542) administration. Since TGF-βR2 and TGF-β1 are known miR-21 targets, we suggest that miR-21 transfer from injured neurons to macrophages maintains a proinflammatory phenotype via suppression of such an antiinflammatory pathway. These data support miR-21 inhibition as a possible approach to maintain polarization of DRG macrophages at an M2-like state and attenuate neuropathic pain.

Authors

Lynda Zeboudj, George Sideris-Lampretsas, Rita Silva, Sabeha Al-Mudaris, Francesca Picco, Sarah Fox, David Chambers, Marzia Malcangio

×

Figure 3

miR-21-5p silencing in macrophages induces activation of the canonical TGF-β signaling pathway.

Options: View larger image (or click on image) Download as PowerPoint
miR-21-5p silencing in macrophages induces activation of the canonical T...
BMDM transfection with antagomir-21 or scramble control for 48 hours followed by TGF-β signaling pathway analysis. (A) TGF-β1 ELISA in culture media of BMDMs transfected with antagomir-21, mimic-21, or scramble control, stimulated with vehicle or LPS (100 ng/mL), n = 4 per group. (B) Immunofluorescent staining of TGF-βR2 in BMDMs transfected with antagomir-21 or scramble control. Bar graph represents quantification of TGF-βR2 fluorescence intensity (n = 4). Scale bar: 50 μm. (C) Immunofluorescent staining of p-SMAD2/3 in BMDMs transfected with antagomir-21 or scramble control. Bar graph represents quantification of p-SMAD2/3 fluorescence intensity (n = 9). Scale bar: 50 μm. (D) Western blotting of SMAD4 in BMDMs not transfected (lipofectamine, Lipo) and transfected with either antagomir-21 or scramble control, treated with vehicle or TGF-βR1 antagonist (SB431542), n = 4 per group. (E) Western blotting for p-ERK/ERK and p-p38/p38 in BMDMs not transfected and transfected with either antagomir-21 or scramble control, n = 4 per group. Data are presented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 by 1-way ANOVA followed by Tukey’s multiple-comparison test (A and D) or unpaired, 2-tailed Student’s t test (B and C).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts